These findings, together with the data present in this study, indicate the important roles of FBP1 expression in cancer development and progression, and the methylation level in FBP1 promoter can serve as a novel biomarker for prognosis and therapeutic target for NSCLC patient. This evidence concerns the gene FBP1 and non-small cell lung carcinoma.